阿帕替尼联合紫杉醇不同时序给药治疗肺癌的实验

目的 观察阿帕替尼联合紫杉醇不同时序给药对肺癌的抗肿瘤效应。方法 建立裸鼠A549肺癌模型，随机分成6组。A：0.9%氯化钠溶液组（0.9%NS, d1~8）。B：单用阿帕替尼组（APa, d1~7）。C：单用紫杉醇组（PTX, d1）。D：联合用药组1（C1组：PTX, d1；APa, d2~8）。E：联合用药组2（同时用药组，C2组：PTX, d1；APa, d1~7）。F：联合用药组3（C3组：APa，D1~7；PTX, d8），治疗结束次日行PET/CT扫描测肿瘤组织SUV值、ELISA检测血中VEGFR-2浓度、免疫组织化学检测肿瘤组织微血管计数、TUNEL法检测肿瘤组织细胞凋亡，绘制肿瘤生长曲线，计算肿瘤抑制率。结果 治疗组移植瘤生长速率较0.9%氯化钠溶液组均有所减慢（P<0.05），联合用药组间抑瘤率差异无统计学意义，联合用药组2凋亡细胞数最多，VEGFR-2浓度、SUV值最低（P<0.05），联合用药组2 MVD-CD31表达最低，与除联合用药组3外的其余各组比较，差异均有统计学意义（P<0.05）。结论 阿帕替尼联合紫杉醇同时用药对肺癌治疗效果最好。

Experiment of Different Administration Sequences of Apatinib and Paclitaxel on Lung Cancer

Objective To observe the anti-tumor effect of apatinib(APa) combined with paclitaxel(PTX) at different sequential dosing on lung cancer. Methods A549 lung cancer nude mice model was established and randomly divided into six groups: A: Control group (0.9% NS, D1-8) ; B: Apatinib alone group ( APa, D1-7); C: Paclitaxel alone group (PTX, D1); D: Combined group 1 (PTX, D1; APa, D2-8); E: Combined group 2 (PTX, D1; APa, D1-7); F: Combinaed group 3 (APa, D1-7; PTX, D8). The day after the end of treatment, we used ELISA to detect the VEGFR2 concentration of blood, immunohistochemistry was used to measure the microvessel number, TUNEL assay was employed to detect the apoptosis cells of tumor, and PET/CT was used to probe SUV value. We observed and drew the tumor growth curve, and then calculated the tumor inhibition rate. Results The tumor growth rate of treatment groups were all significantly slowed, compared with the physiological saline group (P<0.05), and the tumor inhibition rate of all combined groups had no statistically significance compared with each other, respectively. The Combined group 2 showed most apoptotic cells, lowest VEGFR-2 levels and SUV value (P<0.05), while the lowest MVD-CD31 expression in Combined group 2 had statistically significance compared with the physiological saline group, except the Combined group 3 (P<0.05). Conclusion Apatinib combined with paclitaxel shows the best effect on treating lung cancer.